Clinical trial / 2023
Cocoa extract supplementation did not reduce the risk of incident type 2 diabetes in older adults over a median of 3.5 years.
In the COSMOS trial, 18,381 participants free of diabetes at enrollment were randomly assigned to receive daily cocoa extract (500 mg/day cocoa flavanols, including 80 mg (-)-epicatechin) or placebo. Over a median follow-up of 3.5 years, 801 incident type 2 diabetes cases were reported. Compared with placebo, cocoa extract supplementation did not reduce type 2 diabetes risk (adjusted HR 1.04, 95% CI 0.91-1.20, P = 0.58). The effect was not modified by sex, race, BMI, smoking, physical activity, diet quality, baseline flavanol status, or multivitamin assignment.
- Study type
- 2 x 2 factorial randomized clinical trial
- Who was studied
- 18,381 U.S. adults without diabetes at baseline (part of 21,442 participants; women aged >=65, men aged >=60)
- What was measured
- Incident self-reported type 2 diabetes
THE PAPER
Cocoa Extract Supplementation and Risk of Type 2 Diabetes: The Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) Randomized Clinical Trial.
Li J, Sesso HD, Kim E, Manson JE, Friedenberg G, Clar A, Copeland T, Shadyab AH, Wactawski-Wende J, Tinker L, Liu S. Diabetes Care, 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.